ETHNIC DIFFERENCES OF THE CYP2C19 GENE POLYMORPHISM ASSOCIATED WITH THE VIOLATION OF THE RESPONSE TO CLOPIDOGREL IN THE RUSSIAN FEDERATION

Genetically determined diversity in the activity of enzymes regulating the biotransformation of drugs and xenobiotics - cytochrome P450
(CYP) is one of the main causes of interindividual differences in the response of pharmacotherapy. The objective of this review is to analyze
the prevalence of polymorphic markers of gene CYP2C19, associated with the violation of the pharmacological response to clopidogrel among
the various ethnic groups living in the Russian Federation, and to define the prospects of using pharmacogenetic testing in order to improve the
efficiency and safety of antiplatelet therapy in Russian patients with coronary artery disease. According to the result of the studies frequency
of CYP2C19*2 is higher in the Mongolian race (max frequency in Kalmyks is 25,0%). CYP2C19*17 allele was studied in Russians only and
was about the same as in the Caucasian race (14,0%).

K.B. Mirzaev (1), D.A. Sychev (2,3), D.A. Andreev (1)
1 -Sechenov First Moscow State Medical University, Russian Federation, 119991, Moscow, Trubetskaya street, 8/2; 2 -Russian Medical Academy of Postgraduate Education, Russian Federation, 123995, Moscow, Barrikadnaya street, 2/1; 3 -Center for Clinical Pharmacology, Scientific Center on Expertise of Medical Application Products, Russian Federation, 109240, Moscow, Yauzskaya street 11/6